Dilated Cardiomyopathy (DCM) Clinical Trials and Treatments

Dilated cardiomyopathy (DCM) is characterized by dilation and impaired contraction of the left ventricle or both ventricles. The heart muscle stretches and thins, weakening its pumping ability and leading to heart failure. Causes include genetic mutations (especially in titin, lamin A/C, and other structural proteins), viral myocarditis, alcohol use, chemotherapy toxicity, and autoimmune processes, though many cases remain idiopathic.

The most common symptoms of Dilated Cardiomyopathy include Shortness of breath during activity or when lying flat, Fatigue and reduced exercise tolerance, Swelling in the legs, ankles, and feet, Rapid or irregular heartbeat and palpitations, Lightheadedness or dizziness, among others. Approximately 1 in 250 to 1 in 500 people; accounts for about 30-40% of heart failure cases. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Dilated Cardiomyopathy from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. For patients with advanced dilated cardiomyopathy who require LVAD support, one of the biggest ongoing challenges is anticoagulation. Warfarin is currently the only option for LVAD patients, but it is notoriously difficult to manage and carries significant bleeding and clotting risks.

Yes. As of October 21, 2026, 1 FDA-approved medicine has a current label that names Dilated Cardiomyopathy: Corlanor. Corticosteroids and immune globulins count once each.

Dilated Cardiomyopathy is caused by variants in any of many genes, most often TTN, LMNA, MYH7, TNNT2, SCN5A and DES. A genetic cause is found in about 25-35% of cases; truncating TTN variants alone account for 15-20%. Many cases are acquired (myocarditis, ischemia, drugs).

It is autosomal dominant, so each child of an affected parent has a 1 in 2 chance of inheriting it. Approximately 1 in 250 to 1 in 500 people; accounts for about 30-40% of heart failure cases. A multigene panel identifies the cause in most families.

Yes. Dilated Cardiomyopathy can be caused by variants in many different genes (TTN, LMNA, MYH7, TNNT2, SCN5A and DES are among the most common), so testing is usually a multigene panel or exome sequencing rather than one gene at a time. A genetic cause is found in about 25-35% of cases; truncating TTN variants alone account for 15-20%. Many cases are acquired (myocarditis, ischemia, drugs).

It is autosomal dominant, so each child of an affected parent has a 1 in 2 chance of inheriting it.

Knowing the exact gene matters: it decides which trials a patient qualifies for and which relatives should be tested. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Dilated Cardiomyopathy clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Dilated Cardiomyopathy clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.